Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Recombinant DNA01:09

Recombinant DNA

Overview
Production of Pharmaceuticals01:30

Production of Pharmaceuticals

Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The landscape of antibody production systems: recombinant expression for research, diagnostics and therapy.

Frontiers in bioengineering and biotechnology·2026
Same author

Novel bispecific T-cell engagers overcoming acquired EGFR resistance.

mAbs·2026
Same author

Phase I Study Evaluating a Monoclonal Fc-Silenced SARS-CoV-2 Antibody in Patients With Moderate-to-Severe COVID-19.

Clinical therapeutics·2026
Same author

Resolving the Interference of Anti-CD38 Antibodies on Blood Compatibility Assays Using CD38 "Baitbodies" Approach.

Journal of immunology research·2026
Same author

Immunogenic <i>Streptococcus equi</i> cell surface proteins identified by ORFeome phage display.

mSphere·2025
Same author

Phage Display Derived Antibodies Against Antimicrobial Peptide FsPDF2 Reveal Stress Response in European Beech.

Plant biotechnology journal·2025

Related Experiment Video

Updated: May 9, 2026

Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

Expression of recombinant antibodies.

André Frenzel1, Michael Hust, Thomas Schirrmann

  • 1Abteilung Biotechnologie, Institut für Biochemie, Biotechnologie und Bioinformatik, Technische Universität Braunschweig , Braunschweig , Germany.

Frontiers in Immunology
|August 3, 2013
PubMed
Summary

Recombinant antibody production is rapidly advancing beyond mammalian cell lines. Emerging systems in yeast, plants, and bacteria offer promising alternatives for therapeutic protein development.

Keywords:
fungiinsect cellsmammalian cellprocaryotesrecombinant antibodytransgenic organismsyeast

More Related Videos

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells
10:32

Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells

Published on: June 5, 2015

Related Experiment Videos

Last Updated: May 9, 2026

Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells
10:32

Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells

Published on: June 5, 2015

Area of Science:

  • Biotechnology
  • Protein Engineering
  • Immunology

Background:

  • Recombinant antibodies are crucial for research, diagnostics, and therapeutics.
  • Therapeutic antibody production is dominated by mammalian cell lines due to glycosylation concerns.
  • Phage display and other in vitro systems have accelerated antibody generation.

Purpose of the Study:

  • To review current recombinant antibody production systems.
  • To assess the usability of various systems for different applications.
  • To highlight advancements in non-mammalian antibody production.

Main Methods:

  • Review of literature on recombinant antibody production platforms.
  • Analysis of different expression systems including bacteria, yeast, insect cells, plants, and animals.
  • Evaluation of glycosylation patterns and immunogenicity risks.

Main Results:

  • Mammalian cell lines are standard for therapeutic antibodies due to glycosylation control.
  • Glycosylation-engineered yeast, insect cells, and plants show potential for human-like modifications.
  • Bacterial systems efficiently produce non-glycosylated antibody fragments, including bispecific antibodies.

Conclusions:

  • Non-mammalian antibody production systems are nearing clinical application.
  • Advancements in glycosylation engineering are key to overcoming immunogenicity barriers.
  • Diverse recombinant systems offer tailored solutions for antibody production needs.